Moleculin Biotech, Inc. Unrealized Gain (Loss) on Derivatives
Moleculin Biotech, Inc. (MBRX) reported Unrealized Gain (Loss) on Derivatives of $573.00 thousand for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2018-11-13
- Moleculin Biotech, Inc. unrealized gain (loss) on derivatives for the quarter ending 2018-09-30 was $573.00K.
- Moleculin Biotech, Inc. unrealized gain (loss) on derivatives for the quarter ending 2018-06-30 was $331.00K.
- Moleculin Biotech, Inc. unrealized gain (loss) on derivatives for the quarter ending 2017-09-30 was -$470.00K.
- Moleculin Biotech, Inc. unrealized gain (loss) on derivatives for the quarter ending 2017-06-30 was -$3.34M.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month |
|---|---|---|---|
| 2018-09-30 | $573.00K 10-Q · filed 2018-11-13 | $904.00K derived: sum of 2 quarters · filed 2018-11-13 | $1.61M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $331.00K 10-Q · filed 2018-08-10 | $1.04M 10-Q · filed 2018-08-10 | |
| 2017-09-30 | -$470.00K 10-Q · filed 2018-11-13 | -$3.81M derived: sum of 2 quarters · filed 2018-11-13 | -$2.75M 10-Q · filed 2018-11-13 |
| 2017-06-30 | -$3.34M 10-Q · filed 2018-08-10 | -$2.28M 10-Q · filed 2018-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |